Upon infection, mycobacteria, such as Mycobacterium tuberculosis (Mtb) and
nontuberculous mycobacteria (NTM), are recognized by host innate immune cells, triggering …

Despite the availability of M ycobacterium tuberculosis (Mtb) drugs for over 50 years,
tuberculosis (TB) remains at pandemic levels. New drugs are urgently needed for resistant …

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), has co‐evolved with
the human immune system and utilizes multiple strategies to persist within infected cells, to …

Tuberculosis (TB) has been a transmittable human disease for many thousands of years,
and M. tuberculosis is again the number one cause of death worldwide due to a single …

Tuberculosis (TB) is one of the leading causes of mortality and morbidity, particularly in
developing countries, presenting a major threat to the public health. The currently …

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a leading cause of
morbidity and mortality in humans worldwide. Currently, the standard treatment for TB …

Host-directed therapies are a relatively new and promising approach to treatment of
tuberculosis. Modulation of specific host immune pathways, including those that impact …

The emergence and spread of drug-resistant strains of Mycobacterium tuberculosis is
worsening the global threat of tuberculosis (TB). There is a need and urgency for the …

Abstract Treatment of multidrug-resistant tuberculosis (MDR-TB) is extremely challenging
due to the virulence of the etiologic strains of Mycobacterium tuberculosis (M. tb), the …

Tuberculosis (TB) caused by the intracellular pathogen, Mycobacterium tuberculosis (Mtb),
claims more than 1.5 million lives worldwide annually. Despite promulgation of multipronged …